• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Quest Diagnostics Releases 2024 Corporate Responsibility Report

    6/25/25 9:07:00 AM ET
    $DGX
    Medical Specialities
    Health Care
    Get the next $DGX alert in real time by email

    SECAUCUS, N.J., June 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today published its 2024 Corporate Responsibility Report.

    Quest Diagnostics supported diverse initiatives in 2024

    The theme of the report, Care Starts Here, reflects the pivotal role Quest plays in an individual's healthcare, providing insights from laboratory diagnostics to drive well-informed decisions. The report details Quest's accomplishments in 2024 across the company's four strategic pillars of corporate responsibility: health access, employee and community engagement, governance and ethics, and environmental sustainability.  

    "Care runs deep in the Quest culture, energizing our more than 55,000 colleagues to deliver on the Quest Purpose, working together to create a healthier world, one life at a time," said Jim Davis, Chairman, CEO and President. "As this year's report highlights, we created several exciting new innovations and programs in 2024 to improve health quality and access, not only for our patients, but also for our employees and the communities we serve. We look forward to building on this momentum throughout 2025 and beyond."

    In 2024, Quest:

    • Supported nearly 40 programs through the Quest Diagnostics Foundation with organizations committed to improving clinical and community health outcomes
    • Donated approximately $13 million in corporate giving and Foundation grants to organizations focused on disaster relief, health research and local health initiatives
    • Provided approximately one million donated or discounted test requisitions (which often include several tests)
    • Generated employee and corporate donations for over 650 nonprofits through the company's Employee Matching Gifts program
    • Extended its board of directors by welcoming a new director, Robert Carter, a former Executive Vice President and Chief Information Officer for FedEx®, whose expertise in technology and logistics supports Quest's continuous improvement initiatives focused on quality and efficiency
    • Introduced approximately 50 innovative new testing services focused on improving access across several disease areas, including Alzheimer's disease, certain cancers and HIV
    • Spent approximately $300 million on goods and services from small U.S. businesses
    • Reduced usage of electricity and single-use plastics and continued to transition the company's courier fleet in the U.S. to electric and hybrid vehicles
    • Made progress toward securing International Organization for Standardization (ISO) 14001-2015 certification for environmental management for two additional labs in our Marlborough, Massachusetts. and Lewisville, Texas facilities

    To read the full report, click on 2024 Corporate Responsibility Report.

    About Quest Diagnostics

    Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

    questhealth.com logo (PRNewsfoto/Quest Diagnostics)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-releases-2024-corporate-responsibility-report-302490233.html

    SOURCE Quest Diagnostics

    Get the next $DGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DGX

    DatePrice TargetRatingAnalyst
    4/2/2025$195.00Buy
    Redburn Atlantic
    3/4/2025$185.00Buy → Neutral
    Citigroup
    1/6/2025$169.00 → $174.00Market Perform → Outperform
    Leerink Partners
    12/17/2024$145.00 → $172.00Equal-Weight → Overweight
    Morgan Stanley
    12/10/2024$175.00 → $185.00Buy
    Jefferies
    10/23/2024$157.00 → $182.00Neutral → Outperform
    Robert W. Baird
    8/28/2024$165.00In-line
    Evercore ISI
    7/10/2024$145.00 → $165.00Neutral → Buy
    Citigroup
    More analyst ratings

    $DGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Carter Robert B was granted 1,203 shares, increasing direct ownership by 81% to 2,685 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/19/25 4:24:41 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Director Diaz Luis was granted 1,203 shares, increasing direct ownership by 42% to 4,054 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/19/25 4:24:09 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Director Gregg Vicky B was granted 1,203 shares, increasing direct ownership by 7% to 18,138 units (SEC Form 4)

      4 - QUEST DIAGNOSTICS INC (0001022079) (Issuer)

      5/19/25 4:23:35 PM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Quest Diagnostics Releases 2024 Corporate Responsibility Report

      SECAUCUS, N.J., June 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today published its 2024 Corporate Responsibility Report. The theme of the report, Care Starts Here, reflects the pivotal role Quest plays in an individual's healthcare, providing insights from laboratory diagnostics to drive well-informed decisions. The report details Quest's accomplishments in 2024 across the company's four strategic pillars of corporate responsibility: health access, employee and community engagement, governance and ethics, and environme

      6/25/25 9:07:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025

      SECAUCUS, N.J., June 23, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial results on Tuesday, July 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.Q

      6/23/25 10:52:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology

      SECAUCUS, N.J., June 10, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) designed to improve the assessment of elevated risk of cancer in individuals who would benefit from medically appropriate cancer screenings.  Under terms of the agreement, Quest will develop and validate a laboratory-developed blood test based on circulating protein biomarkers associated with high risk for one or more cancers, including colorectal,

      6/10/25 8:03:00 AM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Redburn Atlantic initiated coverage on Quest Diagnostics with a new price target

      Redburn Atlantic initiated coverage of Quest Diagnostics with a rating of Buy and set a new price target of $195.00

      4/2/25 8:51:11 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics downgraded by Citigroup with a new price target

      Citigroup downgraded Quest Diagnostics from Buy to Neutral and set a new price target of $185.00

      3/4/25 7:20:57 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously

      1/6/25 7:49:06 AM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    SEC Filings

    See more
    • SEC Form 11-K filed by Quest Diagnostics Incorporated

      11-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

      6/20/25 4:20:51 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form S-3ASR filed by Quest Diagnostics Incorporated

      S-3ASR - QUEST DIAGNOSTICS INC (0001022079) (Filer)

      6/20/25 4:08:24 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Incorporated filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - QUEST DIAGNOSTICS INC (0001022079) (Filer)

      5/22/25 6:28:25 AM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      2/13/24 5:12:21 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      1/25/24 12:16:40 PM ET
      $DGX
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Quest Diagnostics Incorporated (Amendment)

      SC 13G/A - QUEST DIAGNOSTICS INC (0001022079) (Subject)

      2/7/23 1:25:52 PM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Financials

    Live finance-specific insights

    See more
    • Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025

      SECAUCUS, N.J., June 23, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial results on Tuesday, July 22, 2025, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.Q

      6/23/25 10:52:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Declares Quarterly Cash Dividend

      SECAUCUS, N.J., May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025. About Quest DiagnosticsQuest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take acti

      5/14/25 6:17:00 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025

      First quarter revenues of $2.65 billion, up 12.1% from 2024First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80SECAUCUS, N.J., April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE:DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025. "In the fir

      4/22/25 6:43:00 AM ET
      $DGX
      Medical Specialities
      Health Care

    $DGX
    Leadership Updates

    Live Leadership Updates

    See more
    • Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health

      Study to evaluate how behavioral and sensor data from wearables and blood tests can be leveraged to help individuals better assess and manage their metabolic health SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Fitbit and Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a collaboration to study the potential of wearable devices to improve metabolic health, which influences risk of developing several diseases, including diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair beh

      1/17/24 8:58:00 AM ET
      $DGX
      Medical Specialities
      Health Care
    • Quest Diagnostics Board of Directors Elects James E. Davis Chairman of the Board

      SECAUCUS, N.J., March 3, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive Officer and President, to serve in the additional position of Chairman of the Board of Directors, effective April 1, 2023. "The Board carefully considered our governance structure and determined that combining the roles of Chairman and CEO under Jim Davis's leadership is in the best interest of shareholders to successfully continue to execute

      3/3/23 4:30:00 PM ET
      $DGX
      Medical Specialities
      Health Care
    • Quotient Limited Announces Appointment of Chief Financial Officer

      JERSEY, Channel Islands, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company's Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler who will support the Company during the transitional phase, as needed, before leaving Quotient Limited at year-end. "I am delighted to welcome Ali to the Executive team at this exciting time in our Company's evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career spanning healthcare services and manufacturing. I w

      10/12/21 8:45:00 AM ET
      $DGX
      $QTNT
      Medical Specialities
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances